FHTX

In the past six months (March 2026 to September 2026), Foghorn Therapeutics' stock price was impacted by several events. In March 2026, the company provided a financial and corporate update, highlighting pipeline advancement and a $50 million registered direct financing in January 2026, which extended its cash runway into the first half of 2028. A first-quarter 2026 financial and corporate update in May 2026 noted the progress of FHD-909 and its collaboration with Lilly. In August 2026, Foghorn Therapeutics reported Q2 2026 earnings per share (EPS) of -$0.10, a 64.29% year-over-year increase, with collaboration revenue of $19.3 million for the six months ending June 30, 2026. H.C. Wainwright reaffirmed a "Buy" rating on FHTX in August 2026. The company participated in the Goldman Sachs 47th Annual Global Healthcare Conference in September 2026. Over the last twelve months, the stock price has declined by 11.4%, trading between $3.27 and $7.61, and has underperformed the S&P500 Index by -26.1% over the past six months.